From Health Canada:
Health Canada releases important information on the dispensation of clozapine products in Canada
The Marketed Health Products Directorate (MHPD) and the Therapeutic Products Directorate (TPD) would like to draw your attention to important upcoming revisions to the Product Monographs of all clozapine products marketed in Canada. These revisions will strengthen the labelling and address ongoing issues around patient consent for the sharing of information between registries. As you know, monitoring of patients with the use of registries is the risk mitigation strategy in place to address the known risk of agranulocytosis.